Interruption to antiplatelet therapy early after acute ischaemic stroke: A nested case-control study

Mazlan-Kepli, W., MacIsaac, R. L., Walters, M. , Bath, P. M. W. and Dawson, J. (2017) Interruption to antiplatelet therapy early after acute ischaemic stroke: A nested case-control study. British Journal of Clinical Pharmacology, 83(9), pp. 2045-2055. (doi:10.1111/bcp.13290) (PMID:28299795)

[img]
Preview
Text
138562.pdf - Accepted Version

572kB

Abstract

AIMS Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor compliance, complications or withdrawal of care. It is unclear whether this places patients at increased risk of recurrence. We explored the association between cardiovascular event rate and persistence with prescribed antiplatelet drugs. METHODS We used a matched case-control design using the Virtual International Stroke Trials Archive (VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or transient ischaemic attack within 90 days post-stroke and were matched for age ±10 years and sex with up to four controls. Antiplatelet use was categorized as persistent (used for > 3 days and continued up to day 90), early cessation (used antiplatelet < 3 days) or stopped/interrupted users (used for > 3 days but stopped prior to day 90). These categories were compared in cases and controls using a conditional logistic regression model that adjusted for potential confounders. RESULTS A total of 970 patients were included, of whom 194 were cases and 776 were matched controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users (adjusted OR 0.70, 95% CI 0.33, 1.48; P = 0.352) and early cessations (adjusted OR 1.04, 95% CI 0.62, 1.74; P = 0.876) when compared to persistent users. CONCLUSION We found no increased risk in patients who stopped and interrupted antiplatelets early after stroke but the study was limited by a small sample size and further research is needed.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Macisaac, Dr Rachael and Dawson, Professor Jesse and Walters, Professor Matthew
Authors: Mazlan-Kepli, W., MacIsaac, R. L., Walters, M., Bath, P. M. W., and Dawson, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:British Journal of Clinical Pharmacology
Publisher:Wiley
ISSN:0306-5251
ISSN (Online):1365-2125
Published Online:16 March 2017
Copyright Holders:Copyright © 2017 Wiley
First Published:First published in British Journal of Clinical Pharmacology 83(9): 2045-2055
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record